Immunomedics, Inc. Reports Final Results From Phase Ib/II Study of Yttrium-90-Labeled Clivatuzumab Tetraxetan and Gemcitabine in Advanced Pancreatic Cancer

SAN FRANCISCO, Jan. 20, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that repeated cycles of fractionated doses of its proprietary humanized antibody, clivatuzumab tetraxetan, labeled with yttrium-90 (90Y) and given in combination with gemcitabine, demonstrated therapeutic activity in patients with advanced, inoperable, pancreatic cancer.